The FDA’s Pharmacy Compounding Advisory Committee votes July 23-24 on seven peptides, several of which sit squarely in women’s-health research: MOTS-c (bone, insulin sensitivity), BPC-157 (gut, endometriosis-adjacent interest), DSIP (sleep), and Epitalon (anti-aging). Here’s what actually changes for you under each realistic outcome — not just the headline version.
If MOTS-c Gets a Favorable Recommendation
MOTS-c has drawn specific research interest for its ties to insulin sensitivity and, more recently, bone metabolism — relevant to the osteoporosis risk women face disproportionately after menopause. A favorable vote starts FDA rulemaking toward a legal compounding pathway, but that process typically runs six to eighteen months. It does not create immediate prescribing access.
If BPC-157 Gets a Favorable Recommendation
BPC-157’s gut-healing research profile is part of why it comes up so often in endometriosis and IBS-adjacent conversations among women researching peptides. Same caveat applies: a favorable vote is a process-starter, not an access-creator. Research-use sourcing remains the only current option regardless of the vote’s direction.
If the Outcome Is Mixed or Deferred
Given seven substances split across two days, a uniform result is unlikely. Industry trackers following the FDA’s own pre-meeting briefing documents anticipate a mixed picture — some substances advancing, others deferred pending more human safety data. If that’s the outcome, expect renewed advocacy ahead of the second PCAC meeting scheduled before February 2027, which will review five more peptides including GHK-Cu.
What This Means for Your Own Research
Regardless of outcome, sourcing quality matters just as much this month as it will after the vote. If you’re researching any of the seven peptides under review, vendor transparency and batch-specific documentation are worth prioritizing now.